The female pelvic implants market is projected to account for sales worth USD 258.91 million by 2023. The market is projected to observe a CAGR of 2.8% in the forecast period, reaching USD 341.26 million by 2033.
As per FMI, the top five players comprising Johnson & Johnson, Coloplast A/S, Becton, Dickinson and Company, Boston Scientific Corporation, and Cook Medical constitute around 75% of the overall market.
Market to Gain from Novel Tissue Engineering Launch for Female Pelvic Floor Reconstruction
Ongoing post-marketing surveillance of approved devices and the introduction of novel tissue engineering in female pelvic floor reconstruction creates huge opportunities in the female pelvic implants industry. The majority of manufacturers are selling their products in the global market despite strict regulations.
After the Food and Drug Administration’s (FDA) reclassification of vaginal mesh implants from Class II to Class III medical devices, the FDA has advised 33 manufacturers to conduct 3-year studies. It is to assess the impact of organ damage and other complications of mesh implants.
After assessing the risks, the manufacturers can reintroduce their devices and can get pre-market approval from the FDA. Further, this allows manufacturers to re-launch mesh implants, which are expected to enter the market.
Similarly, the introduction of novel tissue engineering with growth factors, biomaterials, and drugs implanted into tissue damage or loss is set to boost repair time, stimulating the regeneration of damaged tissue.
Studies initiating tissue engineering for pelvic organ prolapse have reported the use of novel designed knit material fabricated from FDA-approved non-degradable polyamide dip-coated in gelatin for MSC seeding and delivery.
Polypropylene mesh commonly used in clinical practice has good mechanical properties, but there are long-term complications. This validates the need for tissue engineering technology in the treatment of pelvic organ prolapse and promotes an innovative approach to pelvic implantation.
What are the Factors Restraining Demand for Female Pelvic Implants?
As per the USFDA, the transvaginal placement of surgical mesh can be risky in women with POP mesh complications. Some of the common complications reported include mesh erosion, infections, vaginal scarring, discomfort and pain during sex, and even a resurgence of urinary incontinence.
Through January 31, 2019, over 139,000 adverse events have been reported for mesh products of which over 69,000 events were reported for POP mesh products, as per FDA, 2020. This restricts the patients from taking surgeries to implant vaginal mesh, thereby deterring market growth.
Growing awareness of surgical complications is curbing patients from opting for vaginal mesh implants in the high-growth markets of Europe and the United States.
| Attributes | Details |
|---|---|
| Female Pelvic Implants Market Size (2023) | USD 258.91 million |
| Female Pelvic Implants Market Size (2033) | USD 341.26 million |
| Female Pelvic Implants Market CAGR (2023 to 2033) | 2.8% |
| Female Pelvic Implants Market Size (2022) | USD 251.86 million |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to Future Market Insights (FMI), the demand for female pelvic implants has grown at a 2.5% CAGR between 2018 and 2022.
According to the Division of Female Pelvic Medicine and Reconstructive Surgery at Northwestern University Chicago, women with normal life expectancy have an average 30-50% chance of developing pelvic organ prolapse.
Around 19% of these women need to undergo at least one surgical intervention for POP or SUI and 30% of them undergo reoperation for recurrence. Despite such high prevalence, there is no definite cure or restoration of anatomical defects for pelvic organ prolapse or stress urinary incontinence.
In the last two decades, many efforts have been made to improve the outcomes of surgery. However, the majority of such efforts have resulted in the use of vaginal mesh and grafts. So far, surgical options with mesh implants and slings are proving to be the best option for such disorders which imply a heavy social and economic burden.
Other surgical options such as allografts and xenografts are costly and carry the potential of transmission of infectious disease and synthetic meshes. Thus, the market for female pelvic implants is expected to see continuous growth in the use of mesh and sling implants until definite alternatives are available for these products.
Future Market Insights expects the global female pelvic implants industry to rise at 2.8% CAGR between 2023 and 2033.
The United States holds over 83% share of the female pelvic implants market in North America. As per the records of the Association for Pelvic Organ Prolapse Support, nearly 34 million women suffer from pelvic organ prolapse (POP) across the globe currently.
In the United States, the overall number of patients with POP is 3.3 million. According to the National Association for Incontinence, 25 million people in the United States suffer from some form of urinary incontinence, out of which 75% are women. Stress urinary incontinence (SUI) is the most prevalent form.
In the United States, about 15 million people are suffering from SUI. Thus, the rising prevalence of pelvic organ prolapse and stress urinary incontinence is driving the United States female pelvic implant market.
The United Kingdom market accounts for over 13% of Europe market through the assessment period ending in 2033. The governments of various countries in Europe like the United Kingdom are forming committees that can address the issues of women suffering from peri-operative complications of surgeries for pelvic implants.
These programs are expected to raise awareness among patients, hospitals, and GPs and can increase the penetration of female pelvic implants over the forecast period. For instance,
India’s market accounts for more than 30% of the sales registered in South Asia in 2021. Most developing countries have patients that are not aware of conditions such as pelvic organ prolapse and stress urinary incontinence.
Perception of pain associated with surgery evokes considerable anxiety in patients resulting in a reluctance to consider surgical options to cure SUI or POP. Many women delay or do not seek treatment for these diseases in India due to a lack of awareness. It is forecasted to be the big challenge for the growth of female pelvic implants in India market.
| Country | Australia |
|---|---|
| Forecast CAGR % (2023 to 2033) | 2.8% |
The market for female pelvic Implants in Australia is exhibiting a 2.8% CAGR and is projected to account for more than 86% of Oceania market throughout the projection period. Growing government initiatives to create awareness are anticipated to boost growth in the region. For instance,
Principal Consultant
| Segment | Vaginal Sling/Tapes |
|---|---|
| Forecast CAGR (2023 to 2033) | 2.5% |
Vaginal sling/tapes have a high growth potential. The segment is likely to expand with a relatively high CAGR of 2.5% in the forthcoming years. Vaginal sling/tape implants are generally made from a narrow ‘tape’ of polypropylene mesh which is placed under the urethra like a sling or hammock to keep the urethra in the correct position.
Vaginal slings have been on the market for about 20 years and can be implanted in half-hour. The minimally invasive surgical procedure under local anesthesia is preferred for outpatient applications. Owing to these advantages, demand for vaginal sling/tapes is increasing during the forecast period.
The stress urinary incontinence (SUI) segment is expected to contribute maximum revenue share in the global female pelvic implants market. In terms of revenue, the stress urinary incontinence (SUI) segment accounted for over 58% share in 2022.
The demand for female pelvic implants is likely to witness solid growth on account of the prevalence of stress urinary incontinence and rising awareness among women regarding treatment options on a global scale.
| Segment | Hospitals |
|---|---|
| Forecast CAGR (2023 to 2033) | 2.2% |
Hospitals are currently the leading end users of female pelvic implants with a 2.2% CAGR through the forecast period. Similarly, hospitals can impact high investment abilities and capital, with the surge in the number of emergency admissions, which is projected to enhance growth prospects for the long term.
Manufacturers are primarily focusing on developing new products to bolster the acceptance of female pelvic implants, thus anticipating the surge in sales figures. Further, the companies are focusing on outsourcing the production of female pelvic implants to reduce manufacturing costs, thereby challenging the market with reduced costs.
Key players are entering into collaborations, partnerships, acquisitions, and mergers to strengthen their product lines and global market.
Key Players Working in the Market:
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Market Analysis | USD Million for Value in Million |
| Key Regions Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania Middle East & Africa |
| Key Countries Covered | The United States, Canada, the United Kingdom, Germany, Italy, France, Spain, Benelux, Russia, India, Thailand, Malaysia, Indonesia, China, Japan, South Korea, Australia, New Zealand, GCC Countries, South Africa and North Africa |
| Key Segments Covered | Product Type, Indication, End User, and Region |
| Key Companies Profiled | Johnson & Johnson Services, Inc.; Coloplast A/S; Dipromed Srl; Boston Scientific Corporation; pfm medical ag; Betatech Medical; Promedon Group; Caldera Medical; Cook Medical |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The CAGR for the market is 2.8% until 2033.
From 2018 to 2022, the market expanded at an 2.5% CAGR.
The market in 2023 totals USD 258.91 million.
Promedon Group, Caldera Medical, Cook Medical are some key players.
The market will reach USD 341.26 million by 2033.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product Type 5.1. Vaginal Mesh Implants 5.2. Vaginal Sling 5.3. Vaginal Graft Implants 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication 6.1. Pelvic Organ Prolapse 6.2. Stress Urinary Incontinence 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 7.1. Hospitals 7.2. Ambulatory Surgical Centres 7.3. Speciality Clinics 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. North America 8.2. Latin America 8.3. Western Europe 8.4. Eastern Europe 8.5. South Asia and Pacific 8.6. East Asia 8.7. Middle East & Africa 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. Middle East & Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16. Key Countries Market Analysis 17. Market Structure Analysis 18. Competition Analysis 18.1. Johnson & Johnson Services, Inc. 18.2. Coloplast A/S 18.3. Dipromed Srl 18.4. Boston Scientific Corporation 18.5. pfm medical ag 18.6. Betatech Medical 18.7. Promedon Group 18.8. Caldera Medical 18.9. Cook Medical 19. Assumptions & Acronyms Used 20. Research Methodology
Healthcare
March 2024
REP-GB-2533
195 pages
Explore Healthcare Insights
View Reports
Female Pelvic Implants Market
